Drugs / MVX01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06337643 | Mar 2023 → Apr 2024 | — | Matrivax Research and Development Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVX01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06337643 ↗ |
| Modality | Vaccine | “MVX01, a pneumococcal vaccine candidate” NCT06337643 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT06337643 ↗ |